292 related articles for article (PubMed ID: 9761295)
1. A new model of proliferative vitreoretinopathy.
Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS
Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295
[TBL] [Abstract][Full Text] [Related]
2. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
Ozerdem U; Mach-Hofacre B; Cheng L; Chaidhawangul S; Keefe K; McDermott CD; Bergeron-Lynn G; Appelt K; Freeman WR
Curr Eye Res; 2000 Jun; 20(6):447-53. PubMed ID: 10980656
[TBL] [Abstract][Full Text] [Related]
3. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of extracellular ATP-induced Müller cell responses in a dispase model of proliferative vitreoretinopathy.
Francke M; Weick M; Pannicke T; Uckermann O; Grosche J; Goczalik I; Milenkovic I; Uhlmann S; Faude F; Wiedemann P; Reichenbach A; Bringmann A
Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):870-81. PubMed ID: 11867610
[TBL] [Abstract][Full Text] [Related]
5. Experimental model for proliferative vitreoretinopathy by intravitreal dispase: limited by zonulolysis and cataract.
Kralinger MT; Kieselbach GF; Voigt M; Hayden B; Hernandez E; Fernandez V; Parel JM
Ophthalmologica; 2006; 220(4):211-6. PubMed ID: 16785750
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.
Shinohara K; Tanaka M; Sakuma T; Kobayashi Y
Ophthalmic Surg Lasers Imaging; 2003; 34(4):299-305. PubMed ID: 12875458
[TBL] [Abstract][Full Text] [Related]
8. EIU in the rat promotes the potential of syngeneic retinal cells injected into the vitreous cavity to induce PVR.
Behar-Cohen FF; Thillaye-Goldenberg B; de Bizemont T; Savoldelli M; Chauvaud D; de Kozak Y
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3915-24. PubMed ID: 11053294
[TBL] [Abstract][Full Text] [Related]
9. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy.
Turgut B; Uyar F; Ustundag B; Celiker U; Akpolat N; Demir T
Retina; 2012 Feb; 32(2):232-41. PubMed ID: 21934553
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
[TBL] [Abstract][Full Text] [Related]
11. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
[TBL] [Abstract][Full Text] [Related]
12. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen R; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4113-8. PubMed ID: 15505063
[TBL] [Abstract][Full Text] [Related]
13. [THE CHARACTERISTICS OF RETINA AT THE DEVELOPMENT OF PROLIFERATIVE VITREORETINOPATHY IN RATS AFTER INTRAOCULAR INJECTION OF CONCANAVALIN A AND DISPASE].
Erdiakov AK; Tikhonovich MV; Rzhavina EM; Gavrilova SA
Ross Fiziol Zh Im I M Sechenova; 2015 May; 101(5):572-85. PubMed ID: 26263683
[TBL] [Abstract][Full Text] [Related]
14. Proliferative vitreoretinopathy in the Swine-a new model.
Umazume K; Barak Y; McDonald K; Liu L; Kaplan HJ; Tamiya S
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4910-6. PubMed ID: 22729438
[TBL] [Abstract][Full Text] [Related]
15. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
Liou GI; Pakalnis VA; Matragoon S; Samuel S; Behzadian MA; Baker J; Khalil IE; Roon P; Caldwell RB; Hunt RC; Marcus DM
Mol Vis; 2002 Dec; 8():494-501. PubMed ID: 12500176
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.
Oshima Y; Sakamoto T; Hisatomi T; Tsutsumi C; Ueno H; Ishibashi T
Gene Ther; 2002 Sep; 9(18):1214-20. PubMed ID: 12215888
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy.
Moritera T; Ogura Y; Yoshimura N; Honda Y; Wada R; Hyon SH; Ikada Y
Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3125-30. PubMed ID: 1399416
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
Zahn G; Volk K; Lewis GP; Vossmeyer D; Stragies R; Heier JS; Daniel PE; Adamis AP; Chapin EA; Fisher SK; Holz FG; Löffler KU; Knolle J
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1028-35. PubMed ID: 19815730
[TBL] [Abstract][Full Text] [Related]
19. Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin.
Kumar A; Tewari HK; Bathwal DP; Khosla PK
Indian J Ophthalmol; 1994 Mar; 42(1):31-5. PubMed ID: 7927629
[TBL] [Abstract][Full Text] [Related]
20. [Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery].
Lleó Pérez A ; Campos Fernández R ; López Santoveña F ; Sánchez Lorente G ; Hernández Martínez FJ ; Navarro Palop C
Arch Soc Esp Oftalmol; 2000 Nov; 75(11):741-750. PubMed ID: 11151263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
